Want to see SEED full AI Analyst Report?
SEED Stock Chart & Stats
$1.32
-$0.10(-5.19%)
At close: 4:00 PM EST
$1.32
-$0.10(-5.19%)
Day’s Range― - ―
52-Week Range$0.82 - $2.49
Previous CloseN/A
Volume43.60K
Average Volume (3M)2.25M
Market Cap
$12.26M
Enterprise Value$82.75M
Total Cash (Recent Filing)$13.37M
Total Debt (Recent Filing)$29.12M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Jan 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding12,143,526
10 Day Avg. Volume6,011,928
30 Day Avg. Volume2,246,586
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.76
Price to Sales (P/S)0.71
P/FCF Ratio-1.80
Enterprise Value/Market Cap6.75
Enterprise Value/Revenue2.41
Enterprise Value/Gross Profit25.06
Enterprise Value/Ebitda-7.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biotech Credentials & Commercial ReadinessHolding a biosafety certificate, production licenses and a restored processing facility materially reduces operational barriers to commercial GMO seed sales and enables near-term scaling. The Marker Consortium creates a pathway to monetize biotech IP beyond direct seed sales, strengthening long-term commercialization options and partnerships.
Deep Breeding Pipeline & Data AssetsA very large, AI-enabled breeding pipeline and extensive germplasm database provide durable R&D productivity and a repeatable engine for new varieties. This scale shortens time-to-market for traits, supports differentiated hybrids, and underpins potential licensing revenue and sustained product introductions over multiple seasons.
Rebuilt Commercial OrganizationInvesting in a dedicated sales force and regional KPI-driven distributor contracts establishes a tangible route to convert R&D into field adoption. A structured commercial rollout and targeted S&M spend improve distribution coverage and farmer engagement, supporting persistent revenue-generation capabilities as new varieties are commercialized.
Bears Say
Stressed Balance SheetNegative equity and a meaningful increase in debt materially reduce financial flexibility and raise refinancing and dilution risk. A contracted asset base since 2023 limits collateral and borrowing capacity, constraining the company’s ability to fund multi-year commercial rollouts and absorb execution delays without external capital.
Weak Cash Generation & Modest LiquidityPersistent operating cash outflows and negative free cash flow mean the business does not self-fund its growth and R&D consistently. With a small cash buffer vs sizable liabilities, the company faces structural financing risk that could force dilutive capital raises or curtailed investment, impairing long-term product commercialization.
Regulatory Dependency For GMO UpsideA core growth thesis rests on GMO regulatory approvals; because timing and scope are policy-dependent, revenue realization is externally constrained. This structural dependency means even strong R&D and sales execution may not translate into commercial revenues until regulators permit broader commercialization or trait deployment.
Origin Agritech News
SEED FAQ
What was Origin Agritech Limited’s price range in the past 12 months?
Origin Agritech Limited lowest stock price was $0.82 and its highest was $2.49 in the past 12 months.
What is Origin Agritech Limited’s market cap?
Origin Agritech Limited’s market cap is $12.26M.
When is Origin Agritech Limited’s upcoming earnings report date?
Origin Agritech Limited’s upcoming earnings report date is Jan 11, 2027 which is in 181 days.
How were Origin Agritech Limited’s earnings last quarter?
Origin Agritech Limited released its earnings results on May 21, 2026. The company reported -$0.172 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.172.
Is Origin Agritech Limited overvalued?
According to Wall Street analysts Origin Agritech Limited’s price is currently Overvalued.
Does Origin Agritech Limited pay dividends?
Origin Agritech Limited does not currently pay dividends.
What is Origin Agritech Limited’s EPS estimate?
Origin Agritech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Origin Agritech Limited have?
Origin Agritech Limited has 12,143,526 shares outstanding.
What happened to Origin Agritech Limited’s price movement after its last earnings report?
Origin Agritech Limited reported an EPS of -$0.172 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Origin Agritech Limited?
Currently, no hedge funds are holding shares in SEED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Origin Agritech Limited
Established in 1997 and headquartered in Beijing, China, Origin Agritech Limited is a Chinese firm operating in two primary areas: agricultural biotechnology and an e-commerce platform. Its biotechnology segment focuses on the genetic enhancement and breeding of crop seeds, encompassing the development, production, and distribution of hybrid crop varieties and associated seed technologies. The firm also manages an e-commerce platform that caters to farmers across China, offering a diverse array of goods via online and mobile channels. This selection includes agricultural seeds like corn, rice, and vegetables, along with essential farming inputs such as fertilizers and agricultural chemicals. Additionally, the platform provides food, household items, and other consumer products. Origin Agritech maintains collaboration agreements with esteemed institutions such as the Chinese Academy of Agricultural Sciences, the National Maize Improvement Center, China Agricultural University, and Zhejiang University.
SEED Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced view: clear operational and structural progress (large cuts in G&A, improved operating loss, strengthened biotech credentials, rebuilt sales force, sizable breeding pipeline and targeted variety acquisitions) alongside meaningful near-term challenges (a 31.9% revenue decline, ongoing net loss, modest cash position, higher inventories and dependency on regulatory timing for GMO commercialization). Management emphasized that the company is in the midpoint of a recovery plan and investing in sales and R&D to convert pipeline into revenue, but realization of that upside remains contingent on execution and policy developments.View all SEED earnings summariesTechnical Analysis
American Vanguard
―
Arcadia Biosciences
―
BioHarvest Sciences
―
Bioceres Crop Solutions
―
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
0.33% Other Institutional Investors
99.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---